Browse All

Current Filters

CLEAR FILTER x

TITLE

Phase 3, Open-Label, Safety Extension Study of Oral Edaravone (Radicava ORS®) Administered Over 96 Weeks in Patients with ALS (MT-1186-A03)

Author:Genge, Angela   Pattee, Gary   Sobue, Gen   Aoki, Masashi   Yoshino, Hiide   Couratier, Philippe   Lunetta, Christian   Petri, Susanne   Selness, Daniel   Todorovic, Vesna   Hirai, Manabu   Salah, Alejandro   Apple, Stephen   Wamil, Art   Kalin, Alexander   Jackson, Carlayne A.   

Session Name:S27: General Neurology 2  

Topic:General Neurology  

Program Number:S27.007  

Author Institution:Montreal Neurological Institute and Hospital, Montreal, QC, Canada  University of Nebraska Medical Center, Lincoln, NE  Nagoya University Graduate School of Medicine, Aichi Medical University, Nagoya, Aichi, Japan  Tohoku University School of Medicine, Sendai, Miyagi, Japan  Neurology Clinic, Chiba, Japan  CRMR SLA Service de Neurologie, CHU de Limoges, Limoges, France  Istituti Clinici Scientifici Maugeri IRCCS, Neurorehabilitation Unit of Milano , Milan, Italy  Hannover Medical School, Hannover, Germany  Mitsubishi Tanabe Pharma America, Inc., Jersey City, NJ  Mitsubishi Tanabe Pharma Europe Ltd., London, United Kingdom  Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan  University of Texas Health Science Center at San Antonio, San Antonio, TX  

Impact of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612) on Motor Function: Efficacy Outcomes from the Phase 3 BouNDless Study

Author:Ellenbogen, Aaron L.   Espay, Alberto J.   Hauser, Robert A.   Stocchi, Fabrizio   Pahwa, Rajesh   Ferreira, Joaquim J.   Kieburtz, Karl   Albanese, Alberto   Giladi, Nir   Salin, Laurence   Sasson, Nissim   Adar, Liat   Vostokova, Natalia   Pereira, Jonathan   Rascol, Olivier   

Session Name:S37: Movement Disorders: Clinical Trials  

Topic:Movement Disorders  

Program Number:S37.001  

Author Institution:Quest Research Institute, Farmington Hills, MI  James J. and Joan A. Gardner Center for Parkinson’s Disease and Movement Disorders, University of Cincinnati, Cincinnati, OH  University of South Florida, Tampa, FL  University San Raffaele Roma and Institute for Research and Medical Care IRCCS San Raffaele, Roma, Italy  University of Kansas Medical Center, Kansas City, KS  Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal  Clintrex Research Corp, Sarasota, FL  Department of Neurology, IRCCS Istituto Clinico Humanitas, Rozzano, Italy  Brain Institute, Tel-Aviv Medical Center Faculty of Medicine, Sagol School of Neurosciences, Tel Aviv University, Tel Aviv, Israel  NeuroDerm Ltd., Rehovot, Israel  Mitsubishi Tanabe Pharma America, Inc., Jersey City, NJ  University of Toulouse 3, University Hospital of Toulouse, INSERM, Clinical Investigation Center CIC1436, Toulouse, France  

Long-term Function and Survival of Radicava ORS® (Oral Edaravone)-Treated Patients With ALS vs Propensity Score–Matched PRO-ACT Historical Controls

Author:Takahashi, Fumihiro   Genge, Angela   Yoneoka, Takatomo   Hirai, Manabu   Selness, Daniel   Todorovic, Vesna   Wamil, Art   Sasson, Nissim   Apple, Stephen   Yoshiteru, Ushirogawa   

Session Name:P8: General Neurology: Motor Neuron Disease 1  

Topic:General Neurology  

Program Number:P8.003  

Author Institution:Mitsubishi Tanabe Pharma America, Inc., Jersey City, NJ  Montreal Neurological Institute and Hospital, Montreal, QC, Canada  Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan  Mitsubishi Tanabe Pharma Europe, Ltd, London, United Kingdom  NStat Solutions, Biostatistical Services, Rehovot, Israel  

Smartphone-Mediated At-Home Telespirometry Erect and Supine Slow Vital Capacity Decline Differences Based On NIV Status in Subjects With ALS

Author:Young, Eufrosina   Wang, Dongliang   Slavinski, George   Manta, Dragos   Sah, Birenda   Desai, Urvi   Deb, Lena   Posmik, Marielle   Collins, Jeffrey   Blystone, Emma   Meyer, Jenny   Narapureddy, Bhavya   Ibrahim, Ahmed   Biso, Grace Marie   Vijaywargiya, Darshana   Abdelhafiz, Sara   

Session Name:P8: General Neurology: Motor Neuron Disease 1  

Topic:General Neurology  

Program Number:P8.004  

Author Institution:SUNY Upstate Medical University, Syracuse, NY  Atrium Health Neurosciences Institute, Charlotte, NC  Mitsubishi Tanabe Pharma Corporation, Tokoyo, Japan  Mitsubishi Tanabe Pharma America, Inc., Jersey City, NJ  Clinical Trials Planning LLC, Charlotte, NC  

Referral Patterns for Patients With Amyotrophic Lateral Sclerosis Enrolled in a US-Based Administrative Claims Database

Author:Novak, John C.   Ciepielewska, Malgorzata   Zhang, Jeffrey   Liu, Ying   DaSilva, Polina   

Session Name:P8: General Neurology: Motor Neuron Disease 1  

Topic:General Neurology  

Program Number:P8.009  

Author Institution:OhioHealth Physician Group, Westerville , OH  Mitsubishi Tanabe Pharma America, Inc., Jersey City, NJ  Princeton Pharmatech, LLC, Princeton, NJ